Economics of pharmacogenomics: Rethinking beyond QALYs?

Current Pharmacogenomics and Personalized Medicine

Volumn 11, Issue 3, 2013, Pages 187-195

  Payne, Katherine ^a   Thompson, Alexander J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cost benefit analysis; Cost effectiveness analysis; Decision making; Economic evaluation; QALYs; Resource allocation

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; TRASTUZUMAB; VEMURAFENIB;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; GASTROINTESTINAL STROMAL TUMOR; HEALTH ECONOMICS; HUMAN; LUNG NON SMALL CELL CANCER; PHARMACOGENOMICS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; STOMACH CANCER; WELFARE;

EID: 84884201305     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/18756921113119990001     Document Type: Article

References (67)

1. Newman WGN. Pharmacogenetics: making cancer treatment safer and more effective. London: Springer 2010.
2. Fargher EA, Tricker K, Newman B, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase (TPMT) testing prior to azathioprine prescription. J Clin Pharm Ther 2007; 32: 187-95.
3. MRC. Developing and evaluating complex interventions: new guidance. MRC: London 2008.
4. Brouwer WB, Culyer AJ, van Exel NJ, et al. Welfarism vs, extra welfarism. J Health Economics 2008; 27(2): 325-38.
5. Ng Y. Welfare economics. Introduction and basic concepts. California: Macmillan 1983.
6. Brouwer WBF, Koopmanschap MA. On the economic foundations of CEA. Ladies and gentlemen, take your positions! Journal of Health Economics. 2000; 19: 439-59.
7. HM Treasury. The Green Book. Appraisal and evaluation in central government. London: TSO 2001.
8. Smith RD, Sach TH. Contingent valuation: what needs to be done? Health Economics Policy and Law 2010; 5: 91-111.
9. Pauly MV. Valuing Health Care Benefits in Money Terms. In: Sloan F, editor. Valuing Health Care. Cambridge: Cambridge University Press 1995.
10. Neumann PJ, Cohen JT, Hammitt JK et al. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ 2012; 21(3): 238-51.
11. Culyer AJ. The normative economics of health care finance and provision. In: McGuire A, Fenn P, Mayhew K. Providing Health Care: The Economics of Alternative Systems of Finance and Delivery. Oxford: Oxford University Press 1991.
12. McCabe C, Claxton K, Culyer AJ. The NICE Cost-Effectiveness Threshold: What it is and what that means. Pharmacoeconomics 2008; 26(9): 733-44.
13. Bowling A. Measuring health: a review of quality of life measurement scales. Maidenhead: McGraw Hill Education 2005.
14. EQ-5D. Available from: http://www.euroqol.org/ [Accessed January 29, 2013]
15. NICE Guide to the methods of technology appraisal. Available from http://www.nice.org.uk/media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf. [Accessed May 9, 2013]
16. Herdman M, Gudex C, Lloyd A et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20(10): 1727-36.
17. Dolan P, et al. A social tariff for EuroQol: results from a UK general population survey. York: University of York Discussion Paper (138) 1995.
18. van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012: 15(5): 708-15.
19. Brazier J, ratcliffe J, Salomon JA, et al. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press 2007.
20. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986; 5(1): 1-30
21. Manca AN, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Economics 2005; 14(5): 487-96.
22. Rawlins M & Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329: 224.
23. Sculpher MJ, Claxton K, Drummond MJ, et al. Whither trial-based economic evaluation for health care decision making? Health Econ 2006; 15(7): 677-87.
24. Dervieux T & Bala M. Overview of the pharmacoeconomics of pharmacogenomics. Pharmacogenomics 2006; 7(8): 1175-84.
25. NICE Diagnostics Assessment Programme Manual. Available from http://www.nice.org.uk/media/A0B/97/DAPManualFINAL.pdf. [Accessed January 29, 2013]
26. Crabb N, Marlow M, et al. The NICE Diagnostics Assessment Programme. Health Policy and Technology 2012; 1(1): 5-7.
27. Merlin T, Farah C, Schubert C, et al. Assessing personalized medicines in Australia: A national framework for reviewing codependent technologies. Medical Decision Making 2012. [Epub ahead of print]
28. Phillips KA & Van Bebber SL. A systematic review of costeffectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 2004; 5(8): 1139-49.
29. Vegter S, Boersma C, Rozenbaum M, et al. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: A systematic review on content and adherence to guidelines. Pharmacoeconomics 2008; 26(7): 569-87.
30. Payne K, Newman WG, Gurwitz D, et al. TPMT testing in azathioprine: a 'cost-effective use of healthcare resources'? Personalized Medicine 2009; 6(1): 103-13.
31. Wong WB, Carlson JJ, Thariani R, et al. Cost effectiveness of pharmacogenomics: A critical and systematic review. Pharmacoeconomics 2010; 28(11): 1001-13.
32. th year anniversary edition of Pharmacogenomics 2010; 11(5): 643-6.
33. Payne K. Fish, chips all round? Regulation of genetic-based technologies. Health Economics 2009; 18(11): 1233-6.
34. National Institute for Health and Care Excellence. www.nice.org.uk, http://www.nice.org.uk/. [Accessed June 10, 2013]
35. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. Available from: http://guidance.nice.org.uk/DT/11. [Accessed January 29, 2013]
36. Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimes in breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat. Available from: http://guidance.nice.org.uk/DT/4. [Accessed January 29, 2013]
37. Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 2006; 24(11): 1121-31.
38. Tsuchiya A & Dolan P. The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature. Med Decis Making 2005; 25: 260-7.
39. Coast J, Smith R, Lorgelly P. Welfarism, extra-welfarism and capability: the spread of ideas in health economics. Soc Sci Med 2008; 67: 1190-98.
40. Dolan P. Developing methods that really do value the 'Q' in the QALY. Health Economics, Policy and Law 2008; 3(1): 69-77.
41. Dolan P. In defence of subjective well-being. Health Economics, Policy and Law 2008; 3(1): 93-95.
42. Dix-Smith M, Drummond M, Brixner D. Moving the QALY forward: rationale for change. Value Health 2009; 12(1): S1-4.
43. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health 2009; 12(1): S5-9.
44. Nord E, Daniels N, Kamlet M. QALYs: some challenges. Value Health 2009; 12(1): S10-5.
45. Kahneman D. A different approach to health state valuation. Value Health 2009; 12(1): S16-7.
46. Lipscomb J, Drummond M, Fryback D, Gold M, Revicki D. Retaining, and enhancing, the QALY. Value Health 2009; 12(1): 18-26.
47. Kind P, Lafata E, Matuszewski K, Raisch D. The use of QALYs in clinical and patient decision-making: issues and prospects. Value in Health 2009; 12(1): s27-s30.
48. Drummond M, Brixner D, Gold M, Kind P, McGuire A, Nord E. Toward a consensus on the QALY. Value Health 2009; 12(1): S31-5.
49. Gold MR, Stevenson D, Fryback D. HALYs and QALYS and DALYs: similarities and differences in summary measures of population health. Annu Rev Public Health 2002; 23: 115-34.
50. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349(9063): 1436-42.
51. Zarate V. DALYs and QALYs in developing countries. Health Aff 2007; 26(4): 1197-98.
52. Mehrez A, Gafni A. The Healthy-years Equivalents. How to Measure Them Using the Standard Gamble Approach. Med Decis Making 1991; 11(2): 140-6.
53. Gafni A & Birch S. Searching for a common currency: critical appraisal of the scientific basis underlying European harmonization of the measurement of health related quality of life (EuroQoL). Health Policy 1993; 23: 219-28.
54. Birch S, Melnikow J, Kuppermann M. Conservative versus aggressive follow up of mildly abnormal Pap smears: testing for process utility. Health Econ 2003; 12: 879-84.
55. Donaldson C, Shackley P. Does process utility exist? A case study of willingness to pay for laparoscopic cholecystectomy. Soc Sci Med 1997; 44(5): 699-707.
56. de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ 2012; 21 (2): 145-72.
57. Flynn TN, Louviere JJ, Peters TJ, et al. 'Best-worst scaling: What it can do for health care research and how to do it'. Journal of Health Economics 2007; 26 (1): 171-189
58. Sen A. Capability and well-being. In the Quality of Life, Nussbaum MC (ed). Oxford: Clarendon Press 1993.
59. ICECAP Capability Measures. Available from: http://www.birmingham.ac.uk/research/activity/mds/projects/HaPS/HE/ICECAP/index.aspx. [Accessed 29 January 2013]
60. Coast J, Flynn TN, Natarajan L, et al. Valuing the ICECAP capability index for older people. Soc Sci Med 2008; 67: 874-82.
61. Drummond MJ, Weatherly H, Ferguson B. A broader perspective should include costs and benefits for all stakeholders. BMJ 2008; 337: 770-1.
62. Mooney G, Lange M. Ante-natal screening: what constitutes benefit. Soc Sci Med 1993; 37(7): 873-8.
63. Hall J, Viney R, Haas M. Taking a count: the evaluation of genetic testing. Aust N Z J Public Health 1998; 22(7): 754-8.
64. Grosse SD, Wordsworth S, Payne K. Economic Methods for Valuing the Outcomes of Genetic Testing: Beyond Cost-Effectiveness Analysis. Genet Med 2008; 10(9): 648-55.
65. Mooney G. What else do we want from our health services? Soc Sci Med 1994; 39(2): 151-4.
66. Fargher EA, Eddy C, Newman W, Qasim F, Tricker K, Elliott RA, Payne K. Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 2007; 8(11): 1511-9.
67. Payne K, Fargher EA, Roberts S, Tricker K, Elliott RA, Ratcliffe J, Newman WG. Valuing pharmacogenetic testing services: A comparison of patients' and healthcare professionals' preferences. Value in Health 2011: 14(1): 121-34.